LATEST
GTCR agreed to acquire CCC Intelligent SolutionsnewEQT agreed to acquire StockbridgenewMubadala Capital acquired Clear Channel OutdoorIthaca Holdings agreed to acquire BumblePenta Fine Ingredients acquired SynerzineHexagon agreed to acquire RocscienceSRS Acquiom / PantaraiSpaceX agreed to acquire nationwide 800 MHz spectrum portfolioAEA Investors acquired RensaWittington Investments agreed to acquire BootsEurazeo / MIYA Water: majority stakeMiddle River Power acquired Panoche Energy Center
Open App
Agreement signedPublished 29 Jul 2026

Processa Pharmaceuticals, Inc. /
Vidya Therapeutics, Inc.

Processa Pharmaceuticals, Inc. Completes Merger With Vidya Therapeutics, Inc.

Buy side: Processa Pharmaceuticals, Inc.
Buy sideProcessa Pharmaceuticals, Inc.
Target: Vidya Therapeutics, Inc.
TargetVidya Therapeutics, Inc.
Processa Pharmaceuticals, Inc. · 29 Jul 2026Source
See the source
Follow Processa Pharmaceuticals, Inc. Follow Vidya Therapeutics, Inc.
Buy side: Processa Pharmaceuticals, Inc.
Buy sideProcessa Pharmaceuticals, Inc.
Target: Vidya Therapeutics, Inc.
TargetVidya Therapeutics, Inc.
01 / BuyerProcessa Pharmaceuticals, Inc.
02 / TargetVidya Therapeutics, Inc.
Source for the buyer and target: Processa Pharmaceuticals, Inc.

For the buyer and target.

“On July 28, 2026, Processa Pharmaceuticals, Inc., a Delaware corporation (the “ Company ” or “ Processa ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among the Company, Venus Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ Merger Sub I ”), Venus Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“ Merger Sub II ”), and Vidya Therapeutics, Inc., a Delaware corporation (“ Vidya ”).”

Published 29 Jul 2026

Open the source
01

What happened

The July 28, 2026 merger made Vidya Therapeutics, Inc. a wholly owned subsidiary of Processa Pharmaceuticals, Inc. [01]

At closing, Processa Pharmaceuticals, Inc. issued Vidya stockholders 558,398 common shares and 142,744.100 shares of Series A Non-Voting Convertible Preferred Stock. Each preferred share is to become convertible into 1,000 common shares, subject to stockholder approval. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. Completes Merger With Vidya Therapeutics, Inc.

This document is the source for the companies, stage and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Also stated

    “Processa Pharmaceuticals, Inc. Completes Merger With Vidya Therapeutics, Inc. The July 28, 2026 merger made Vidya Therapeutics, Inc. a wholly owned subsidiary of Processa Pharmaceuticals, Inc. At closing, Processa Pha…”

    Open the source

  2. Published by Processa Pharmaceuticals, Inc.

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.

04

Deal Web

Every firm and person on this deal, and how they connect. Open any name to see their other deals.

Deal Web · 2 firms · 0 peopleHover a name to see how it connects
This dealProcessa Pharmaceuticals, Inc. / Vidya Therapeutics, Inc.Agreement signed · Published 29 Jul 2026
BuyerProcessa Pharmaceuticals, Inc.TargetVidya Therapeutics, Inc.
This dealProcessa Pharmaceuticals, Inc. / Vidya Therapeutics, Inc.

Agreement signed · Processa Pharmaceuticals, Inc. / Vidya Therapeutics, Inc. deal (Agreement signed, published 29 Jul 2026).

Published 29 Jul 2026
Timeline
  1. Also stated
  2. Published by Processa Pharmaceuticals, Inc.
Hover or tap a name to see how it connects, and when
Deal Web as a list